RxDoctor Payments Data

Srinivas Prasad Jolepalem, MD

Internal Medicine · Darien, ILNPI 1568531564

Payments from drug & device makers

$1,813in general payments, 2019–2025

Across 98 payments — averaging $18.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$482
  • Vanda Pharmaceuticals Inc.$274
  • Sumitomo Pharma America, Inc.$267
  • AstraZeneca$244
  • Exact Sciences$88
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$81
  • plus $377 from 14 others

What the payments were for

  • Food & beverage$1,813100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,813 in reported general payments places this provider in the 80th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$127,223
Medicare patients
296
Services billed
1,077

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide109$162,863
EliquisApixaban166$114,184
TrulicityDulaglutide43$68,863
FarxigaDapagliflozin Propanediol61$61,864
JardianceEmpagliflozin117$59,066
LinzessLinaclotide52$51,906
OzempicSemaglutide39$44,233
EntrestoSacubitril/Valsartan27$38,217
RybelsusSemaglutide12$29,847
GemtesaVibegron40$24,861
MyrbetriqMirabegron48$23,550
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog191$21,337
Breo ElliptaFluticasone/Vilanterol33$20,872
TradjentaLinagliptin38$19,631
Tresiba Flextouch U-100Insulin Degludec31$18,495

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$482$231,727152 claims
AstraZenecaFarxiga, Symbicort$244$80,346114 claims
Novo NordiskOzempic, Rybelsus$74$74,08051 claims
AbbVieLinzess, Creon$19$61,85768 claims
GSKBreo Ellipta, Incruse Ellipta, Anoro Ellipta$24$37,39373 claims
Sumitomo Pharma America, Inc.Gemtesa$267$24,86140 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Darien

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →